PCOS
Conditions
Interventions
HRT:Endothelial preparation using a hormone replacement program
GnRH-a HRT:Endothelial preparation using a GnRH-a hormone replacement program
LE:Endothelial preparation with letrozole
Sponsors
Department of Obstetrics and Gynecology, Second Affiliated Hospital of Air Force Military Medical University
Eligibility
Sex/Gender
Female
Age
20 Years to 38 Years
Inclusion criteria
Inclusion criteria: (1) <38 years of age; (2) Diagnosis of PCOS after exclusion of other endocrine disorders and fulfillment of 2 of the Rotterdam criteria: polycystic changes of the ovaries (PCOM); clinical manifestations of hyperandrogenism and/or hyperandrogenemia; and menstrual abnormalities such as sporadic ovulation or anovulation; (3) Patients with indications for IVF/ICSI-FET procedure; (4) Hysteroscopy within 12 months did not show significant abnormalities; (5) Patients and their families voluntarily participated in this study, understood the related rights and risks, and signed an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Presence of unilateral or bilateral hydrosalpinx without surgical removal or ligation of the fallopian tubes; (2) Women with previously diagnosed uterine abnormalities such as uterine malformations (unicornuate uterus, uterine septum, bicornuate uterus, or bicornuate uterus), adenomyosis, submucous fibroids, or uterine adhesions, endometriosis, untreated endometrial polyps, and endometritis; (3) Previous endometrial thickness <7 mm; (4) Women with abnormal chromosomal karyotypes but not chromosomal polymorphisms or their partners; (5) Repeated spontaneous abortions (including biochemical pregnancies) and repeated implantation failures (defined as 3 or more spontaneous abortions and embryo implantation failures); (6) Women with contraindications to assisted reproductive technology and/or pregnancy disorders such as poorly controlled type 1 or type 2 diabetes mellitus; undiagnosed liver disease or dysfunction (based on serum liver enzyme test results); renal disease or abnormal serum renal function; severe anemia; history of deep vein thrombosis, pulmonary embolism, or cerebral vascular accident; uncontrolled hypertension or known symptomatic heart disease; (or suspected) history of cervical, endometrial or breast cancer history; undiagnosed vaginal bleeding; (7) Use of combination medications or any other condition that, in the opinion of the investigator, interferes with the conduct of the trial or does not ensure the safety and validity of the data, as well as patients who are unable to comply with study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| pregnancy outcome;neonatal outcome;Safety indicators; | — |
Countries
China
Contacts
Public ContactJu Ying
Department of Obstetrics and Gynecology, Second Affiliated Hospital of Air Force Military Medical University
Outcome results
None listed